Avifavir Included in the List of Nationally Recommended Drugs for Treatment of coronavirus

Avifavir Included in the List of Nationally Recommended Drugs for Treatment of coronavirus

June 6, 2020 331

The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group announce Avifavir (based on Favipiravir active substance) has been included in the seventh edition of the Ministry of Health’s guidelines for the prevention, diagnosis and treatment of new coronavirus infection COVID-19.

Avifavir has shown high efficacy in clinical trials, disrupting the reproduction mechanisms of coronavirus. On May 29, 2020, Avifavir received a registration certificate from the Ministry of Health of the Russian Federation and became the first Favipiravir-based drug in the world approved for treatment of COVID-19.

The first batches of Avifavir will be sent to Russian hospitals from June 11, 2020 and they will receive 60,000 courses of the drug during the month. The intermediate data from the Avifavir clinical trials confirms its high efficacy against COVID-19. The final stage of Avifavir clinical trials involving 330 patients in 35 medical centers, approved by the Russian Ministry of Health on May 21, 2020, is ongoing.

  • According to the results of the 10 days of the clinical trials, Avifavir demonstrated safety with no new or previously unreported side effects detected;
  • Median elimination of the virus took four days compared to nine days with standard therapy, according to the study;
  • Efficacy of the drug is above 80%, a criterion for a drug with high antiviral activity;
  • Following the first four days of treatment, 65% of the 40 patients who took Avifavir tested negative for coronavirus, which is twice as many as in the standard therapy group. By day 10, the number of patients whose tests returned negative results reached 90%;
  • The body temperature of 68% of patients taking Avifavir returned to normal earlier (on the third day) than in the control group (on the sixth day);
  • The drug is undergoing trials in Moscow, Saint-Petersburg, Tver, Nizhny Novgorod, Smolensk, Ryazan, Kazan, Ufa and in the Republic of Dagestan.


Information source: here